Chronic myelogenous leukemia that occurred two years after the diagnosis of Adult Still's Disease

Internal Medicine

Volumn 44, Issue 9, 2005, Pages 994-997

  Nakagawa, Yoshifumi ^a   Furusyo, Norihiro ^a,b   Taniai, Hiroaki ^a   Henzan, Hideho ^c   Tsuchihashi, Takuya ^a   Hayashi, Jun ^a,b  

^a KYUSHU UNIVERSITY HOSPITAL   (Japan)

^b KYUSHU UNIVERSITY   (Japan)

^c KYUSHU UNIVERSITY   (Japan)

Author keywords

Adult Still's disease; Chronic myelogenous leukemia; Cyclophosphamide; Cyclosporine

Indexed keywords

ANTIBIOTIC AGENT; BCR ABL PROTEIN; CIPROFLOXACIN; CYCLOPHOSPHAMIDE; CYCLOSPORIN; IMATINIB; MEROPENEM; METHYLPREDNISOLONE; PREDNISOLONE; STEROID;

ADULT; ADULT ONSET STILL DISEASE; ARTHRALGIA; ARTICLE; BACTERIAL INFECTION; BONE MARROW BIOPSY; CANCER DIAGNOSIS; CANCER REGRESSION; CASE REPORT; CELL HYPERPLASIA; CHRONIC MYELOID LEUKEMIA; CLINICAL PROTOCOL; DISEASE CONTROL; FEVER; GRANULOCYTE; HOSPITAL ADMISSION; HOSPITAL DISCHARGE; HUMAN; HUMAN TISSUE; LEUKOCYTE COUNT; LEUKOCYTOSIS; MALE; RELAPSE;

ADULT; CYCLOSPORINE; DRUG RESISTANCE; GENES, ABL; HUMANS; LEUKEMIA, MYELOID, CHRONIC; LEUKEMIA, MYELOID, PHILADELPHIA-POSITIVE; MALE; STEROIDS; STILL'S DISEASE, ADULT-ONSET; TIME FACTORS;

EID: 27844539347     PISSN: 09182918     EISSN: 13497235     Source Type: Journal    
DOI: 10.2169/internalmedicine.44.994     Document Type: Article

References (16)

1. Bywaters EG. Still's disease in the adult. Ann Rheum Dis 30: 121-133, 1971.
2. Sawayama Y, Nabeshima S, Taniai H, Furusyo N, Kashiwagi S, Hayashi J. A Japanese case of severe refractory adult Still's disease: scrum interleukin-18 is a possible marker of the response to low-dose cyclosporin A therapy. Fukuoka Igaku Zasshi 93: 189-195, 2002.
3. Scheinberg MA, Chapira E, Fernandes ML, Hubscher O. Interleukin 6: a possible marker of disease activity in adult onset Still's disease. Clin Exp Rheumatol 14: 653-655, 1996.
4. Kraus A, Alarcon-Segovia D. Fever in adult onset Still's disease. Response to methotrexate. J Rheumatol 18: 918-920, 1991.
5. Shojania K, Chalmers A, Rangno K. Cyclosporin A in the treatment of adult Still's disease. J Rheumatol 22: 1391-1392, 1995.
6. Konopka JB, Watanabe SM, Witte ON. An alteration of the human cabl protein in K562 leukemia cells unmasks associated tyrosine kinase activity. Cell 37: 1035-1042, 1984.
7. Radich JP, Gooley T, Bryant E, et al. The significance of bcr-abl molecular detection in chronic myeloid leukernia patients "late, 18 months or more after transplantation. Blood 98: 1701-1707, 2001.
8. Yamaguchi M, Ohta A, Tsunematsu T, et al. Preliminary criteria for classification of adult Still's disease. J Rheumatol 19: 424-430, 1992.
9. Leandro MJ, Isenberg DA. Rheumatic diseases and malignancy - is there an association? Scand J Rheumatol 30: 185-188, 2001.
10. Zwanenburg TS, Suter W, Matter BE. Absence of genotoxic potential for cyclosporine in experimental systems. Transplant Proc 20: 931-933, 1988.
11. Penn I. Cancers after cyclosporine therapy. Transplant Proc 20: 276-279, 1988.
12. Landewe RB, van den Borne BE, Breedveld FC, Dijkmaus BA. Does cyclosporin A cause cancer? Nat Med 5: 714, 1999.
13. Paul C, Hornig F. Risk of malignancy associated with cyclosporin use in psoriasis. Dermatology 198: 320-321, 1999.
14. Sugawara T, Tsukada T, Wakita Y, et al. A case of myelodysplastic syndrome progressing to acute myelocytic leukemia in which adult-onset Still's disease had occurred 6 years before. Int J Hematol 59: 53-57, 1993.
15. Ikeda Y, Sakemi T, Matsuzaki M, Sano M. Acute myelogenous leukemia following treatment with cyclosporin A in a nephrotic patient. Intern Med 41: 722-724, 2002.
16. Numata A, Shimoda K, Gondo H, et al. Therapy-related chronic myelogenous leukemia following autologous stem cell transplantation for Ewing's sarcoma. Brit J Haematol 117: 613-616, 2002.